Evaluation of patients with zygomycosis

Zygomycosis is a severe angioinvasive infection caused by Zygomycetes. We retrospectively investigated 16 cases of zygomycosis. Materials and methods: The data of patients, who had been followed between 2004 and 2010 in 8 tertiary-care teaching hospitals, were reviewed. Demographic characteristics, underlying diseases, and clinical signs and symptoms of the patients, as well as diagnostic methods, data obtained by radiological imaging methods, and the therapies, were recorded. Therapeutic approaches, antifungal agents and duration of use, and the characteristics of the cases were identified. Results: The study included 11 female and 5 male subjects. The most common symptoms and clinical signs were fever (n = 9) and retro-orbital pain (n = 7). Rhinocerebral zygomycosis was the most common form. The mean time elapsed for diagnosis was 14.26 ± 13.96 (range: 2-52) days. Antifungal therapy was given to 15 patients (94%). In addition to antifungal therapy, 12 patients underwent surgical intervention 1 to 4 times. The mean duration of receiving antifungal therapy was 61.4 ± 58.02 (range: 1-180) days. The median duration of treatment was 62.5 (range: 42-180) days in survivors. Conclusion: Zygomycosis is an infectious disease with high mortality despite antifungal therapy and surgical interventions.

Anahtar Kelimeler:

Key words: Zygomycosis, predisposing factors, Zygomycetes

Evaluation of patients with zygomycosis

Keywords:

Key words: Zygomycosis, predisposing factors, Zygomycetes,

PDF

___

Meis JF, Chakrabarti A. Changing epidemiology of an emerging infection: zygomycosis. Clin Microbiol Infect 2009; 15: 10–14. Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, Desenclos JC, Lortholary O. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis 2009; 15: 1395–1401.
Sundaram C, Mahadevan A, Laxmi V, Yasha TC, Santosh V, Murthy JM, Prohit AK, Mohandas S, Shankar SK. Cerebral zygomycosis. Mycoses 2005; 48: 396–407.
Elinav H, Zimhony O, Cohen MJ, Marcovich AL, Benenson S. Rhinocerebral mucormycosis in patients without predisposing medical conditions: a review of the literature. Clin Microbiol Infect 2009; 15: 693–697.
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653.
Mohindra S, Mohindra S, Gupta R, Bakshi J, Gupta SK. Rhinocerebral mucormycosis: the disease spectrum in 27 patients. Mycoses 2007; 50: 290–296.
Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17: 517–525.
Kontoyiannis DP, Lewis RE. Agents of mucormycosis and entomophthoramycosis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA, USA: Churchill Livingstone; 2010. pp. 3257–3269.
Mantadakis E, Samonis G. Clinical presentation of zygomycosis. Clin Microbiol Infect 2009; 15: 15–20.
Turunc T, Demiroglu YZ, Aliskan H, Colakoglu S, Arslan H. Eleven cases of mucormycosis with atypical clinical manifestations in diabetic patients. Diabetes Res Clin Pract 2008; 82: 203–208.
Singh N, Aguado JM, Bonatti H, Forrest G, Gupta KL, Safdar N, John GT, Pursell KJ, Munoz P, Patel R et al. Zygomycosis in solid organ transplant recipients: a prospective, matched casecontrol study to assess risks for disease and outcome. J Infect Dis 2009; 200: 1002–1011.
Abbas Z, Jafri W, Rasool S, Abid S, Hameed I. Mucormycosis in patients with complicated cirrhosis. Singapore Med J 2007; 48: 69–73.
Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA, D’Souza O. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol 2003; 51: 231–236.
Kok J, Gilroy N, Halliday C, Lee OC, Novakovic D, Kevin P, Chen S. Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae. J Infect 2007; 55: 33–36.
Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859–1867.
Petrikkos G, Skiada A, Sambatakou H, Toskas A, Vaiopoulos G, Giannopoulou M, Katsilambros N. Mucormycosis: tenyear experience at a tertiary-care center in Greece. Eur J Clin Microbiol Infect Dis 2003; 22: 753–756.
Alfano C, Chiummariello S, Dessy LA, Bistoni G, Scuderi N. Combined mucormycosis and aspergillosis of the rhinocerebral region. In Vivo 2006; 20: 311–315.
Maiorano E, Favia G, Capodiferro S, Montagna MT, Lo Muzio L. Combined mucormycosis and aspergillosis of the orosinonasal region in a patient affected by Castleman disease. Virchows Arch 2005; 446: 28–33.
Zhan HX, Lv Y, Zhang Y, Liu C, Wang B, Jiang YY, Liu XM. Hepatic and renal artery rupture due to Aspergillus and Mucor mixed infection after combined liver and kidney transplantation: a case report. Transplant Proc 2008; 40: 1771– 17